Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole

Journal of Medicinal Chemistry

Volumn 47, Issue 25, 2004, Pages 6239-6247

  Pagano, Mario A ^a   Andrzejewska, Mariola ^c   Ruzzene, Maria ^a   Sarno, Stefania ^a   Cesaro, Luca ^a   Bain, Jenny ^b   Elliott, Matthew ^b   Meggio, Flavio ^a   Kazimierczuk, Zygmunt ^c,d   Pinna, Lorenzo A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

^c Agricultural University   (Poland)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4,5,6,7 TETRABROMOBENZIMIDAZOLE; BENZIMIDAZOLE DERIVATIVE; CASEIN KINASE II; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; DERIVATIZATION; DNA ADDUCT; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REARRANGEMENT; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PLEIOTROPY; POLARIZATION; RESIDUE ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BENZIMIDAZOLES; CASEIN KINASE II; CATALYTIC DOMAIN; HUMANS; JURKAT CELLS; KINETICS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PHOSPHORYLATION; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 9744244918     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049854a     Document Type: Article

References (32)

1. Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912-1934.
2. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355-65.
3. Cohen, P. Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. 2002, 1, 309-315.
4. Fabbro, D.; Garcia-Echeverria C. Targeting protein kinases in cancer therapy. Curr. Opin. Drug Discovy Dev. 2002, 5, 701-12.
5. Druker, B. J.; Talpaz, M.; Resta, D. J.; Peng, B.; Buchdunger, E.; Ford, J. M.; Lydon, N. B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C. L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 2001, 344, 1031-1037.
6. Pinna, L. A. The raison d'etre of constitutively active protein kinases: The lesson of CK2. Acc. Chem. Res. 2003, 36, 378-84.
7. Meggio, F.; Pinna, L. A. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003, 17, 349-368.
8. Litchfield, D. W. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem. J. 2003, 369, 1-15.
9. Seldin, D. C.; Leder, P. Casein kinase IIα transgene-induced murine lymphoma: Relation to Theilleriosis in cattle. Science 1995, 267, 894-897.
10. Kelliher, M. A.; Seldin, D. C.; Leder, P. Tal-1 induces cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J. 1996, 15, 5160-5166.
11. Landesman-Bollag, E.; Channavajhala, P. L.; Cardiff, R. D.; Seldin, D. C. p53 deficiency and misexpression of protein kinase CK2 alpha collaborate in the development of thymic lymphomas in mice. Oncogens 1998, 16, 2965-2974.
12. Orlandini, M.; Semplici, F.; Ferruzzi, R.; Meggio, F.; Pinna, L. A.; Oliviero, S. Protein kinase CK2α' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J. Biol. Chem. 1998, 273, 21291-21297.
13. Guo, C.; Yu, S.; Wang, H.; Davis, A. T.; Green, J. E.; Ahmed, K. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J. Biol. Chem. 2001, 276, 5992-5999.
14. Tawfic, S.; Yu, S.; Wang, H.; Faust, R.; Davis, A.; Ahmed, K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001, 16, 573-582.
15. Battistutta, R.; Sarno, S.; De Moliner, E.; Papinutto, E.; Zanotti, G.; Pinna, L. A. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J. Biol. Chem. 2000, 275, 29618-29622.
16. De Moliner, E.; Moro, S.; Sarno, S.; Zagotto, G.; Zanotti, G.; Pinna, L. A.; Battistutta, R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J. Biol. Chem. 2003, 278, 1831-1836.
17. Battistutta, R.; De Moliner, E.; Sarno, S.; Zanotti, G.; Pinna, L. A. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci. 2001, 10, 2200-2206
18. Sarno, S.; De Moliner, E.; Ruzzene, M.; Pagano, M. A.; Battistutta, R.; Bain, J.; Fabbro, D.; Schoepfer, J.; Elliott, M.; Furet, P.; Meggio, F.; Zanotti, G.; Pinna, L. A. Biochemical and 3D-structural data on the specific inhibition of protein kinase CK2 by ((5-oxo-5,6-dihydro-indolo(1,2-a)quinazolin- 7-yl)acetic acid) (IQA). Biochem. J. 2003, 374, 639-646.
19. Sarno, S.; Reddy, H.; Meggio, F.; Ruzzene, M.; Davies, S. P.; Donella-Deana, A.; Shugar, D.; Pinna, L. A. Selectivity of 4,5,6,7- tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ("casein kinase-2"). FEBS Lett. 2001, 496, 44-48.
20. Meggio, F.; Pagano, M. A.; Moro, S.; Zagotto, G.; Dal Ben, D.; Ruzzene, M.; Sarno, S.; Donella Deana, A.; Brunati, A. M.; Pinna, L. A. Unpublished results.
21. Ruzzene, M.; Penzo, D.; Pinna, L. A. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem. J. 2002, 364, 41-47.
22. Mishra, S.; Reichert, A.; Cunnick, J.; Senadheera, D.; Hemmeryckx, B.; Heisterkamp, N.; Groffen, J. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene 2003, 22, 8255-8262.
23. Andrzejewska, M.; Pagano, M. A.; Meggio, F.; Brunati, M.; Kazimierczuk, Z. Polyhalogenobenzimidazoles: Synthesis and their inhibitory activity against casein kinases. Bioorg. Med. Chem. 2003, 11, 3997-4002.
24. Pease, H. L.; Gardiner, J. A. Fluorometric and Colorimetric Procedures for Determination Residues of Benomyl. J. Agr. Food Chem. 1969, 17, 267-270.
25. Meggio, F.; Shugar, D.; Pinna, L. A. Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. Eur. J. Biochem. 1990, 187, 89-94.
26. Szyszka, R.; Grankowski, N.; Felczak, K.; Shugar, D. Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CKI and CKII from Saccharomyces cerevisiae and other sources. Biochem. Biophys. Res. Commun. 1995, 208, 418-424.
27. Davies, S. P.; Reddy, H.; Caivano, M.; Cohen, P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000, 351, 95-105.
28. Agullo, G.; Gamet-Payrastre, L.; Manenti, S.; Viala, C.; Remesy, C.; Chap, H.; Payrastre, B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem. Pharmacol. 1997, 53, 1649-1657.
29. Meggio, F.; Donella Deana, A.; Pinna, L. Endogenous phosphate acceptor proteins for rat liver cytosolic casein kinases. J. Biol. Chem. 1981, 256, 11958-11961.
30. Sarno, S.; Vaglio, P.; Meggio, F.; Issinger, O.-G.; Pinna, L. A. Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J. Biol. Chem. 1996, 271, 10595-10601.
31. Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specificities of protein kinase inhibitors: An update. Biochem. J. 2003, 371, 199-204.
32. Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.